- Characteristics of studies included in the meta-analysis to assess prevalence of JAK2 mutation among blood donors.
| No. | References/Author | Study design | Number of centers | Country | Study duration |
|---|---|---|---|---|---|
| 1 | Zanella et al 198613 | Case-control | Single | Italy | Unspecified |
| 2 | Tagariello et al 200610 | Prospective cohort | Single | Italy | 1 year |
| 3 | Sidon et al 200617* | Cross-sectional | Unspecified | Belgium | Unspecified |
| 4 | Bianchi et al 200718* | Prospective cohort | Single | Italy | Unspecified |
| 5 | Magnussen et al 201319 | Prospective cohort | Single | Denmark | 2 years |
| 6 | Al-Rubaie et al 201420 | Prospective cohort | Single | Iraq | 7 months |
| 7 | Olkhovskiy et al 20159 | Prospective cohort | Single | Russia | 1 month |
| 8 | Kamaruzzaman et al 201811 | Prospective cohort | Two | Malaysia | 9 months |
| 9 | Kandasamy et al 201921 | Prospective cohort | Single | India | 4 months |
| 10 | Gadaam et al 202222 | Prospective cohort | Single | India | 18 months |
| 11 | Hopkins et al 200712* | Prospective cohort | Single | USA | Unspecified |
| No. | References/Author | Sample source and cutoffs used | Total sample size | Individuals with JAK2 mutation +ve/total number tested (%) | Individuals diagnosed with PV | JAK2 analysis assay type |
|---|---|---|---|---|---|---|
| 1 | Zanella et al 198613 | Consecutive repeat blood donors | 81 | No testing for JAK2 | 3 | NA |
| 2 | Tagariello et al 200610 | Out of 5,636 repeat donors, 103 (1.8%) had high HCT (>50% for M and >46% for F), and 79 regular donors as control. | 103 High HCT / Normal HCT 79 | 1/182 (0.55%) | 0 | ARMS amplification refractory mutations system PCR |
| 3 | Sidon et al 200617* | Healthy blood donors | 52 (57 recruited but 5 samples rejected) | 5/52 (9.60%) | NA | Quantitative PCR |
| 4 | Bianchi et al 200718* | Consecutive repeat blood donors with (HCT > 0.47 for M and > 0.42 for F or platelet count >300x109/L) on at least 2 occasions within 1 year. | 177 | 10/177 (5.65%) | NA | Allele-specific (PCR) |
| 5 | Magnussen et al 201319 | Repeat Blood donors with Hb >16.5 g/dl for F and > 18.5 g/dl for M. | 46 | 1/46 (2.20%) | 2 | Unspecified |
| 6 | Al-Rubaie et al 201420 | Male blood donors with HCT ≥ 48% | 94 | 20/94 (21.30%) | NA | Allele-specific Oligonucleotide Real-time quantitative PCR |
| 7 | Olkhovskiy et al 20159 | Healthy blood donors | 1150 | 5/1150 (0.65%) | NA | Allele-specific real time (PCR-RV) |
| 8 | Kamaruzzaman et al 201811 | Out of 2238 blood donors, 175 (7.8%) blood donors had high Hb > 16.5g/dl for M,> 13.8g/dl for f). 45 of these donors (highest counts) were then tested for JAK2 mutation. | 175 | 0/45 (0%) | NA | Allele-specific Oligonucleotide PCR |
| 9 | Kandasamy et al 201921 | Out of 7,076 donors, 112 males with Hb ≥ 18 g/dL were deferred and considered for the study.108 donors with persistent Hb ≥ 18 g/dL at least after 1 month, with no secondary causes of polycythemia were included. | 108 (but only 24 were tested) | 0/24(0%) | NA | Real-time PCR |
| 10 | Gadaam et al 202222 | Out of 13,798 donors, 185 were deferred for Hb > 18 g/dl, those with persistent Hb >18 g/dl after 3 months were tested for JAK2 | 48 | 2/48 (4.10%) | NA | Real-time PCR |
| 11 | Hopkins et al 200712* | Healthy Blood donors | 181 | 0/181 (0%) | NA | Real-time quantitative PCR |
M: males, F: females, HCT: hematocrit, Hb: hemoglobin, PCR: polymerase chain reaction, PV: polycythemia vera, USA: United States of America, JAK2: JAK2V617F
↵* Abstract studies.